Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials. J Thromb Thrombolysis. 806. Patti G, Sticchi A, Bisignani A, Pelliccia F, Pasceri V, Speciale G, Penco M. Meta-regression to identify patients deriving the greatest benefit from dual antiplatelet therapy after stroke or transient ischemic attack without throm- bolytic or thrombectomy treatment. Am J Cardiol. 2019;124:627 635. doi: 807. Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Jonasson J, Minematsu K, Molina CA, et al; SOCRATES Steering Committee and Investigators. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med. 2016;375:35 43. doi: 808. Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina CA, Wang Y, Johnston SC. Ticagrelor added to aspirin in acute ischemic stroke or transient ischemic attack in prevention of dis- abling stroke: a randomized clinical trial. JAMA Neurol. 2020;78:1 9. doi: 809. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, et al; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377:1319 1330. doi: 810. Joubert J, Reid C, Barton D, Cumming T, McLean A, Joubert L, Barlow J, Ames D, Davis S. Integrated care improves risk-factor modification after stroke: initial results of the Integrated Care for the Reduction of Secondary Stroke model. J Neurol Neurosurg Psychiatry. 2009;80:279 284. doi: 811. Joubert J, Davis SM, Donnan GA, Levi C, Gonzales G, Joubert L, Hankey GJ. ICARUSS: An effective model for risk factor man- agement in stroke survivors. Int J Stroke. 2020;15:438 453. doi: 812. 